Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance

Amrutkar, 2019, Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells, BMC Cancer, 19, 10.1186/s12885-019-5803-1 Apte, 2012, Pancreatic stellate cells: a starring role in normal and diseased pancreas, Front. Physiol., 3, 10.3389/fphys.2012.00344 Apte, 2013, A starring role for stellate cells in the pancreatic cancer microenvironment, Gastroenterology, 144, 1210, 10.1053/j.gastro.2012.11.037 Assaraf, 2006, The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis, Drug Resist. Updat., 9, 227, 10.1016/j.drup.2006.09.001 Assaraf, 2019, The multi-factorial nature of clinical multidrug resistance in cancer, Drug Resist. Updat, 46, 10.1016/j.drup.2019.100645 Avan, 2013, Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma, Cancer Res, 73, 6745, 10.1158/0008-5472.CAN-13-0837 Avan, 2013, Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back, Int. J. Cancer, 133, 1016, 10.1002/ijc.28078 Beatty, 2021, The biological underpinnings of therapeutic resistance in pancreatic cancer, Genes Dev., 35, 940, 10.1101/gad.348523.121 Berg, 2020, Microbiome definition re-visited: old concepts and new challenges, Microbiome, 8 Bergman, 2002, Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine), Drug Resist. Updat., 5, 19, 10.1016/S1368-7646(02)00002-X Bhatt, 2020, Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy, Proc. Natl. Acad. Sci. USA, 117, 7374, 10.1073/pnas.1918095117 Bhattacharjee, 2021, Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts, J. Clin. Invest., 131, 10.1172/JCI146987 Bijlsma, 2015, The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal, Cancer Metastas. Rev., 34, 97, 10.1007/s10555-014-9541-1 Binenbaum, 2015, Gemcitabine resistance in pancreatic ductal adenocarcinoma, Drug Resist. Updat., 23, 55, 10.1016/j.drup.2015.10.002 Boyd, 2022, Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment, Semin. Cancer Biol., 82, 184, 10.1016/j.semcancer.2021.03.006 Buchta Rosean, 2019, Impact of the microbiome on cancer progression and response to anti-cancer therapies, Adv. Cancer Res, 143, 255, 10.1016/bs.acr.2019.03.005 Camblin, 2018, Dual Inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer, Clin. Cancer Res, 24, 2873, 10.1158/1078-0432.CCR-17-2262 Cao, 2015, HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer, Oncol. Rep., 33, 1883, 10.3892/or.2015.3789 Caparello, 2016, FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer, World J. Gastroenterol., 22, 6987, 10.3748/wjg.v22.i31.6987 Capello, 2015, Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma, J. Natl. Cancer Inst., 107, 10.1093/jnci/djv132 Catenacci, 2015, Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic Cancer, J. Clin. Oncol., 33, 4284, 10.1200/JCO.2015.62.8719 Chandler, 2019, The double edge sword of fibrosis in cancer, Transl. Res., 209, 55, 10.1016/j.trsl.2019.02.006 Chandra, 2021, Therapeutic potential of microbial modulation in pancreatic cancer, Gut, 70, 1419, 10.1136/gutjnl-2019-319807 Chapa-González, 2022, A review on the efficacy and safety of nab-paclitaxel with gemcitabine in combination with other therapeutic agents as new treatment strategies in pancreatic cancer, Life, 12, 10.3390/life12030327 Ciccolini, 2016, Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective, Cancer Chemother. Pharm., 78, 10.1007/s00280-016-3003-0 Comandatore, 2022, Potential role of exosomes in the chemoresistance to gemcitabine and nab-paclitaxel in pancreatic cancer, Diagnostics, 12, 10.3390/diagnostics12020286 Coppola, 2017, A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer, Drug Resist. Updat., 31, 43, 10.1016/j.drup.2017.07.001 Corty, 2020, Antibacterial use is associated with an increased risk of hematologic and gastrointestinal adverse events in patients treated with gemcitabine for stage IV pancreatic cancer, Oncologist, 25, 579, 10.1634/theoncologist.2019-0570 Cullin, 2021, Microbiome and cancer, Cancer Cell, 39, 1317, 10.1016/j.ccell.2021.08.006 Dalin, 2019, Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance, Cancer Res, 79, 5723, 10.1158/0008-5472.CAN-19-0960 Danesi, 2009, Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors, Pharmacogenomics, 10, 69, 10.2217/14622416.10.1.69 Dangi-Garimella, 2011, Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2, Cancer Res, 71, 1019, 10.1158/0008-5472.CAN-10-1855 Dangi-Garimella, 2013, Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression, PLoS One, 8, 10.1371/journal.pone.0064566 Das, 2021, Therapeutic strategies to overcome taxane resistance in cancer, Drug Resist. Updat., 55, 10.1016/j.drup.2021.100754 De Jesus-Acosta, 2020, Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma, Br. J. Cancer, 122, 498, 10.1038/s41416-019-0683-3 Desai, 2006, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel, Clin. Cancer Res., 12, 1317, 10.1158/1078-0432.CCR-05-1634 Dickson, 2018, Microbiome promotes pancreatic cancer, Nat. Rev. Gastroenterol. Hepatol., 15, 328, 10.1038/s41575-018-0013-x Donadioa, 2022, Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door, Ecancermedicalscience, 16 Duluc, 2015, Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance, EMBO Mol. Med., 7, 735, 10.15252/emmm.201404346 El Hassouni, 2019, Pharmacogenetics of treatments for pancreatic cancer, Expert Opin. Drug Metab. Toxicol., 15, 437, 10.1080/17425255.2019.1620731 Elnaggar, 2012, Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations, Curr. Pharm. Des., 18, 2811, 10.2174/138161212800626175 Elsland, 2018, Bacterial infections and cancer, EMBO Rep., 19, 10.15252/embr.201846632 Elyada, 2019, Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts, Cancer Discov., 9, 1102, 10.1158/2159-8290.CD-19-0094 Erttmann, 2016, Loss of the DNA damage repair kinase ATM impairs inflammasome-dependent anti-bacterial innate immunity, Immunity, 45, 106, 10.1016/j.immuni.2016.06.018 Farrell, 2009, Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer, Gastroenterology, 136, 187, 10.1053/j.gastro.2008.09.067 Firuzi, 2019, Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells, Cancers, 11, 10.3390/cancers11050638 Forouzesh, 2021, Mammalian dihydropyrimidine dehydrogenase, Arch. Biochem. Biophys., 714 Frances, 2020, The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy?, Mol. Ther., 28, 357, 10.1016/j.ymthe.2019.11.026 Frese, 2012, Nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer, Cancer Disco, 2, 260, 10.1158/2159-8290.CD-11-0242 Funamizu, 2012, Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels, PLoS One, 7, 10.1371/journal.pone.0037424 García-González, 2017, Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics, Cell, 169, 431, 10.1016/j.cell.2017.03.046 Geller, 2017, Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine, Science, 357, 1156, 10.1126/science.aah5043 Genovese, 2017, Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins, Drug Resist. Updat., 32, 23, 10.1016/j.drup.2017.10.003 Gieniec, 2019, Cancer-associated fibroblasts-heroes or villains?, Br. J. Cancer, 121, 293, 10.1038/s41416-019-0509-3 Giovannetti, 2021, Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems, Expert Opin. Drug Metab. Toxicol., 17, 867, 10.1080/17425255.2021.1948731 Giovannetti, 2017, Never let it go: stopping key mechanisms underlying metastasis to fight pancreatic cancer, Semin. Cancer Biol., 44, 43, 10.1016/j.semcancer.2017.04.006 Gore, 2014, Pancreatic cancer stroma: friend or foe?, Cancer Cell, 25, 711, 10.1016/j.ccr.2014.05.026 Grasso, 2017, Drug resistance in pancreatic cancer: Impact of altered energy metabolism, Crit. Rev. Oncol. Hematol., 114, 139, 10.1016/j.critrevonc.2017.03.026 Greenhalf, 2014, Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial, J. Natl. Cancer Inst., 106, 10.1093/jnci/djt347 Greten, 2019, Inflammation and cancer: triggers, mechanisms, and consequences, Immunity, 51, 27, 10.1016/j.immuni.2019.06.025 Grunnet, 2015, TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas, Scand. J. Gastroenterol., 50, 485, 10.3109/00365521.2014.980318 Gu, 2021, Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer, Cancer Lett., 521, 98, 10.1016/j.canlet.2021.08.029 Guenther, 2020, Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study, Br. J. Cancer, 1239, 1370, 10.1038/s41416-020-01029-7 Gui, 2015, Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model, Genet. Mol. Res., 14, 5642, 10.4238/2015.May.25.16 Hanahan, 2022, Hallmarks of Cancer: New Dimensions, Cancer Disco, 12, 31, 10.1158/2159-8290.CD-21-1059 Hernández-Camarero, 2021, Cancer: a mirrored room between tumor bulk and tumor microenvironment, J. Exp. Clin. Cancer Res., 40, 10.1186/s13046-021-02022-5 Hesler, 2016, TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3, Carcinogenesis, 37, 1041, 10.1093/carcin/bgw093 Hidalgo, 2015, SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial, Clin. Cancer Res., 21, 4811, 10.1158/1078-0432.CCR-14-3222 Hingorani, 2018, HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma, J. Clin. Oncol., 36, 359, 10.1200/JCO.2017.74.9564 Hu, 2015, Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice, J. Biosci., 40, 269, 10.1007/s12038-015-9518-4 Huang, 2017, TGFβ promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1, Oncogene, 36, 2202, 10.1038/onc.2016.378 Huang, 2019, Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients, Oncoimmunology, 8, 10.1080/2162402X.2019.1665973 Huanwen, 2009, Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines, Mol. Cancer, 8, 10.1186/1476-4598-8-125 Iida, 2013, Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment, Sciences, 342, 967, 10.1126/science.1240527 Iida, 2022, Correction: pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics, Oncogene, 41 Imai, 2020, Antibiotics improve the treatment efficacy of oxaliplatin-based but not irinotecan-based therapy in advanced colorectal cancer patients, J. Oncol., 2020, 10.1155/2020/1701326 Jacobetz, 2013, Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer, Gut, 62, 112, 10.1136/gutjnl-2012-302529 Jacouton, 2017, Probiotic strain lactobacillus casei BL23 prevents colitis-associated colorectal cancer, Front. Immunol., 8, 10.3389/fimmu.2017.01553 Jaramillo, 2018, How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?, Cancer Drug Resist., 1, 6, 10.20517/cdr.2018.02 Kasper, 2020, Colorectal cancer-associated anaerobic bacteria proliferate in tumor spheroids and alter the microenvironment, Sci. Rep., 10, 10.1038/s41598-020-62139-z Kelly, 2006, TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer, Cancer Res, 66, 3859, 10.1158/0008-5472.CAN-05-3948 Kesh, 2020, Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma, Microb. Cell Fact., 19, 10.1186/s12934-020-01330-3 Khorana, 2019, Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update, J. Clin. Oncol., 37, 2082, 10.1200/JCO.19.00946 Kim, 2014, Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma, Clin. Cancer Res, 20, 5937, 10.1158/1078-0432.CCR-14-1269 Kim, 2016, SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic cancer xenografts, Mol. Cancer Ther., 15, 680, 10.1158/1535-7163.MCT-15-0764 Kim, 2021, Microbiome markers of pancreatic cancer based on bacteria-derived extracellular vesicles acquired from blood samples: a retrospective propensity score matching analysis, Biology, 10, 10.3390/biology10030219 Ko, 2016, A phase I study of FOLFIRINOX Plus IPI-926, a Hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma, Pancreas, 45, 370, 10.1097/MPA.0000000000000458 Le Large, 2016, Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment, Expert Rev. Mol. Diagn., 16, 733, 10.1080/14737159.2016.1175940 Lehouritis, 2015, Local bacteria affect the efficacy of chemotherapeutic drugs, Sci. Rep., 51, 1 Lepeltier, 2020, Nanomedicine to target multidrug resistant tumors, Drug Resist. Updat, 52, 10.1016/j.drup.2020.100704 Li, 2009, Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes, J. Neurosci. Res., 87, 1997, 10.1002/jnr.22029 Li, 2016, Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies, Drug Resist. Updat., 27, 14, 10.1016/j.drup.2016.05.001 Li, 2022, The interplay between inflammation and stromal components in pancreatic cancer, Front. Immunol., 13 Macchini, 2021, Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants, Cancer Treat. Rev., 100, 10.1016/j.ctrv.2021.102262 Mace, 2013, Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner, Cancer Res, 73, 3007, 10.1158/0008-5472.CAN-12-4601 Mackey, 1998, Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines, Cancer Res, 58, 4349 Makihara, 2017, Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients, Cancer Chemother. Pharmacol., 80, 527, 10.1007/s00280-017-3388-4 Mathijssen, 2001, Clinical pharmacokinetics and metabolism of irinotecan (CPT-11), Clin. Cancer Res. . J. Am. Assoc. Cancer Res., 7, 2182 Meijer, 2020, Plasma miR-181a-5p downregulation predicts response and improved survival after FOLFIRINOX in pancreatic ductal adenocarcinoma, Ann. Surg., 271, 1137, 10.1097/SLA.0000000000003084 Meijer, 2019, Tumor microbiome: pancreatic cancer and duodenal fluids contain multitudes, …but do they contradict themselves?, Crit. Rev. Oncol. Hematol., 144, 10.1016/j.critrevonc.2019.102824 Milella, 2022, Evolving pancreatic cancer treatment: From diagnosis to healthcare management, Crit. Rev. Oncol. Hematol., 169, 10.1016/j.critrevonc.2021.103571 Mitsunaga, 2013, Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer, Br. J. Cancer, 108, 2063, 10.1038/bjc.2013.174 Mizutani, 2022, Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma, BMC Cancer, 22, 10.1186/s12885-022-09272-2 Mizutani, 2019, Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis, Cancer Res., 79, 5367, 10.1158/0008-5472.CAN-19-0454 Mohindroo, 2021, Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients, Cancer Med, 10, 5041, 10.1002/cam4.3870 Moon, 2021, Catechol enhances chemo‑ and radio‑sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells, Oncol. Rep., 45, 1133, 10.3892/or.2021.7924 Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J. Clin. Oncol., 25, 1960, 10.1200/JCO.2006.07.9525 Mucciolo, 2020, The dark side of immunotherapy: pancreatic cancer, Cancer Drug Resist., 3, 491 Neesse, 2013, CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer, Proc. Natl. Acad. Sci. U. S. A., 110, 12325, 10.1073/pnas.1300415110 Neesse, 2014, SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice, Gut, 63, 974, 10.1136/gutjnl-2013-305559 Nejman, 2020, The human tumor microbiome is composed of tumor type-specific intracellular bacteria, Science, 368, 973, 10.1126/science.aay9189 Neuzillet, 2013, Stromal expression of SPARC in pancreatic adenocarcinoma, Cancer Metastas-.-. Rev., 10.1007/s10555-013-9439-3 Neuzillet, 2019, Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma, J. Pathol., 248, 51, 10.1002/path.5224 Notta, 2016, A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns, Nature, 538, 378, 10.1038/nature19823 Nussinov, 2021, Anticancer drug resistance: an update and perspective, Drug Resist. Updat, 59, 10.1016/j.drup.2021.100796 Öhlund, 2017, Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer, J. Exp. Med., 214, 579, 10.1084/jem.20162024 Olive, 2009, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer, Science, 324, 1457, 10.1126/science.1171362 Özdemir, 2014, Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival, Cancer Cell, 25, 719, 10.1016/j.ccr.2014.04.005 Pant, 2014, A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors, Ann. Oncol. J. Eur. Soc. Med. Oncol., 25, 1416, 10.1093/annonc/mdu157 Pecoraro, 2021, GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer, Drug Resist. Updat, 58, 10.1016/j.drup.2021.100779 Pedroso, 2015, Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice, Microbiology, 161, 1950, 10.1099/mic.0.000149 Peters, 2000, Basis for effective combination cancer chemotherapy with antimetabolites, Pharmacol. Ther., 87, 227, 10.1016/S0163-7258(00)00086-3 Pinedo, 1988, Fluorouracil: biochemistry and pharmacology, J. Clin. Oncol., 6, 1653, 10.1200/JCO.1988.6.10.1653 Poore, 2020, Microbiome analyses of blood and tissues suggest cancer diagnostic approach, Nature, 579, 567, 10.1038/s41586-020-2095-1 Poplin, 2013, Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity, J. Clin. Oncol., 31, 4453, 10.1200/JCO.2013.51.0826 Pothula, 2020, Pancreatic stellate cells: aiding and abetting pancreatic cancer progression, Pancreatology, 20, 409, 10.1016/j.pan.2020.01.003 Pushalkar, 2018, The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression, Cancer Discov., 8, 403, 10.1158/2159-8290.CD-17-1134 Rahib, 2014, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, 74, 2913, 10.1158/0008-5472.CAN-14-0155 Rahman, 2011, Modulation of NF-κB signalling by microbial pathogens, Nat. Rev. Microbiol., 9, 291, 10.1038/nrmicro2539 Ramanathan, 2019, Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313, J. Clin. Oncol., 37, 1062, 10.1200/JCO.18.01295 Randazzo, 2020, Open sesame?: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity of gemcitabine in pancreatic cancer, Cancers, 12, 1, 10.3390/cancers12113206 Rhim, 2014, Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma, Cancer Cell, 25, 735, 10.1016/j.ccr.2014.04.021 Richards, 2017, Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells, Oncogene, 36, 1770, 10.1038/onc.2016.353 Riquelme, 2019, Tumor microbiome diversity and composition influence pancreatic cancer outcomes, Cell, 178, 795, 10.1016/j.cell.2019.07.008 Sahai, 2020, A framework for advancing our understanding of cancer-associated fibroblasts, Nat. Rev. Cancer, 20, 174, 10.1038/s41568-019-0238-1 Schreyer, 2022, Deconstructing pancreatic cancer using next generation-omic technologies-from discovery to knowledge-guided platforms for better patient management, Front. Cell Dev. Biol., 9, 10.3389/fcell.2021.795735 Sepich-Poore, 2021, The microbiome and human cancer, Science, 371, 10.1126/science.abc4552 Sherman, 2014, Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy, Cell, 159, 80, 10.1016/j.cell.2014.08.007 Sinn, 2015, Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial, Eur. J. Cancer, 51, 1546, 10.1016/j.ejca.2015.05.005 Sobocki, 2021, Pancreatic cancer and gut microbiome-related aspects: a comprehensive review and dietary recommendations, Nutrients, 13, 10.3390/nu13124425 Su, 2021, Novel nanomedicines to overcome cancer multidrug resistance, Drug Resist. Updat, 58 Sun, 2012, Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?, World J. Gastroenterol., 18, 4944, 10.3748/wjg.v18.i35.4944 Takeda, 1992, Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay, Biochem. Biophys. Res. Commun., 184, 618, 10.1016/0006-291X(92)90634-W Tezuka, 2018, Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer, Am. J. Cancer Res., 8, 2096 Ting, 2022, Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes, Gut, 71, 1412, 10.1136/gutjnl-2021-326264 Valm, 2012, CLASI-FISH: principles of combinatorial labeling and spectral imaging, Syst. Appl. Microbiol., 35, 496, 10.1016/j.syapm.2012.03.004 Van Cutsem, 2020, Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma, J. Clin. Oncol., 38, 3185, 10.1200/JCO.20.00590 Vande Voorde, 2015, Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs, FEBS Open Bio, 5, 634, 10.1016/j.fob.2015.07.007 Vanlancker, 2016, 5-Fluorouracil sensitivity varies among oral micro-organisms, J. Med. Microbiol., 65, 775, 10.1099/jmm.0.000292 Vennin, 2019, CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan, Nat. Commun., 10, 10.1038/s41467-019-10968-6 Versteijne, 2022, Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial, J. Clin. Oncol., 40, 1220, 10.1200/JCO.21.02233 Von Ahrens, 2017, The role of stromal cancer-associated fibroblasts in pancreatic cancer, J. Hematol. Oncol., 10, 10.1186/s13045-017-0448-5 Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N. Engl. J. Med., 369, 1691, 10.1056/NEJMoa1304369 Wallace, 2010, Alleviating cancer drug toxicity by inhibiting a bacterial enzyme, Science, 330, 831, 10.1126/science.1191175 Wang, 2021, Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance, Drug Resist. Updat, 54, 10.1016/j.drup.2021.100743 Westphalen, 2012, Genetically engineered mouse models of pancreatic cancer, Cancer J., 18, 502, 10.1097/PPO.0b013e31827ab4c4 Wong, 2017, Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (PEGPH20, Curr. Oncol. Rep., 19, 10.1007/s11912-017-0608-3 Xavier, 2022, The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells, Drug Resist. Updat, 62, 10.1016/j.drup.2022.100833 Xian, 2017, Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis, Cancer Lett., 385, 65, 10.1016/j.canlet.2016.11.006 Xu, 2020, Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro, Life Sci., 263, 10.1016/j.lfs.2020.118523 Yao, 2022, c-Myc-PD-L1 axis sustained gemcitabine-resistance in pancreatic cancer, Front. Pharm., 13, 10.3389/fphar.2022.851512 Yu, 2017, Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy, Cell, 170, 548, 10.1016/j.cell.2017.07.008 Yuan, 2018, The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer, Biomed. Pharmacother., 108, 184, 10.1016/j.biopha.2018.08.165 Zaura, 2015, Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces, MBio, 6, 10.1128/mBio.01693-15 Zaura, 2021, Optimizing the quality of clinical studies on oral microbiome: a practical guide for planning, performing, and reporting, Periodontol, 2000, 210, 10.1111/prd.12359 Zeng, 2019, Chemoresistance in pancreatic cancer, Int. J. Mol. Sci., 20 Zgurskaya, 2009, Multicomponent drug efflux complexes: architecture and mechanism of assembly, Future Microbiol, 4, 919, 10.2217/fmb.09.62 Zhang, 2018, Tumor-stroma IL1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer, Cancer Res., 78, 1700, 10.1158/0008-5472.CAN-17-1366 Zhang, 2015, Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells, Oncotarget, 6, 3085, 10.18632/oncotarget.3099 Zhang, 2019, Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3, Expr. Colorectal Cancer. J. Exp. Clin. Cancer Res., 38, 14, 10.1186/s13046-018-0985-y